Over the last five years Valeant Pharmaceuticals International Inc. has gone from a small Canadian dermatology company to a large multi-national conglomerate. This transformation was due to CEO Michael Pearson's vision of acquiring growth instead of focusing on in-house R&D.
Since Biovail Corp. bought Valeant in a reverse merger in June 2010, the new iteration of Valeant has been one of the most acquisitive companies in the industry, completing...